+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Psoriasis Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 566 Pages
  • May 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 5310782
The global market for Psoriasis Treatment was estimated at US$27.5 Billion in 2025 and is projected to reach US$54.3 Billion by 2032, growing at a CAGR of 10.2% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Psoriasis Treatment Market - Key Trends & Drivers Summarized

Why Is the Psoriasis Treatment Market Gaining Prominence in Dermatology?

The psoriasis treatment market is gaining prominence in dermatology due to the increasing prevalence of psoriasis and the growing awareness of the condition among both patients and healthcare providers. Psoriasis is a chronic autoimmune disease characterized by the rapid growth of skin cells, leading to the formation of scaly patches, redness, and inflammation. With rising rates of obesity, metabolic syndrome, and other comorbidities that exacerbate psoriasis, the demand for effective treatment options is on the rise. As healthcare professionals become more attuned to the complexities of psoriasis and its impact on patients’ quality of life, there is a growing emphasis on developing and providing comprehensive treatment strategies that encompass both physical and psychological aspects.

One of the primary factors driving the growth of the psoriasis treatment market is the increasing availability of innovative therapies, including biologics, systemic medications, and topical treatments. Recent advancements in medical research have led to the development of targeted therapies that address specific pathways involved in the pathogenesis of psoriasis. Biologics, which are derived from living cells, have revolutionized the treatment landscape by offering effective and long-lasting solutions for moderate to severe psoriasis. These new therapies not only improve symptoms but also significantly enhance the overall quality of life for patients, driving the adoption of psoriasis treatments in clinical practice.

How Are Technological Advancements and Innovations Shaping the Psoriasis Treatment Market?

Technological advancements and innovations are significantly shaping the psoriasis treatment market by improving treatment options, enhancing patient monitoring, and personalizing care. One notable development is the evolution of biologic therapies, which target specific components of the immune system to reduce inflammation and skin cell proliferation. This class of medications has expanded treatment options for patients with moderate to severe psoriasis, providing more effective and tailored solutions. The introduction of oral biologics and biosimilars is also expected to increase access to treatment and reduce costs, further driving market growth.

Additionally, advancements in telemedicine and digital health technologies are transforming the way psoriasis is managed. Remote consultations and digital monitoring tools enable healthcare providers to assess patients’ conditions more efficiently, ensuring timely adjustments to treatment plans. Mobile applications and wearable devices that track symptoms and treatment adherence are becoming increasingly popular, empowering patients to take control of their condition. This trend towards personalized and remote care is enhancing the overall treatment experience for psoriasis patients and contributing to the growth of the market.

Moreover, ongoing research and development efforts in the field of psoriasis are leading to the discovery of new therapeutic targets and treatment modalities. Clinical trials are continuously exploring novel compounds and combination therapies that offer improved efficacy and safety profiles. The expansion of treatment options, including emerging therapies and novel drug formulations, is expected to enhance patient outcomes and satisfaction. This focus on innovation and research is a critical driver of growth in the psoriasis treatment market.

Furthermore, the increasing emphasis on holistic approaches to psoriasis management is shaping treatment strategies. Healthcare providers are recognizing the importance of addressing not only the physical symptoms but also the psychological and emotional impact of psoriasis. Integrating mental health support, lifestyle modifications, and complementary therapies into treatment plans is becoming more common. This comprehensive approach is driving the demand for multifaceted treatment solutions that can effectively address the complexities of psoriasis.

What Role Do Market Dynamics and Regulatory Trends Play in Shaping the Adoption of Psoriasis Treatments?

Market dynamics and regulatory trends play a crucial role in shaping the adoption of psoriasis treatments as industries respond to changing demands for effective therapies and compliance with regulations. The increasing prevalence of psoriasis is a key driver of the market, with millions of individuals affected worldwide. As healthcare providers become more aware of the need for effective treatment options, the adoption of advanced therapies is becoming essential. The ability to provide comprehensive treatment solutions that address the diverse needs of psoriasis patients is enhancing the market`s appeal and driving adoption.

Regulatory pressures surrounding drug approvals and safety standards are also influencing the adoption of psoriasis treatments. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established stringent guidelines for the approval and monitoring of psoriasis therapies. Compliance with these regulations is essential for manufacturers seeking to bring new products to market. The focus on rigorous testing and safety profiles enhances consumer confidence in available treatments, driving their adoption among healthcare providers and patients.

The competitive landscape within the dermatology and biopharmaceutical industries is another significant factor shaping the adoption of psoriasis treatments. Numerous manufacturers are entering the market, offering a wide range of treatment options tailored to specific patient needs. This competition is driving innovation and improvements in product quality, allowing manufacturers to meet the diverse requirements of different sectors. The focus on product differentiation, including the development of novel biologics and combination therapies, is enhancing the market presence of psoriasis treatments and contributing to their widespread adoption.

Consumer preferences for effective, reliable, and safe psoriasis treatments are also influencing adoption. As patients become more informed about their treatment options, there is a growing demand for therapies that provide fast and long-lasting results. Manufacturers are responding by developing treatments that offer improved efficacy and safety profiles, including options that minimize side effects. The ability to provide high-quality psoriasis treatments that meet the evolving needs of consumers is essential for manufacturers looking to gain a competitive edge in the market.

What Factors Are Driving the Growth of the Global Psoriasis Treatment Market?

The growth in the global psoriasis treatment market is driven by several factors, including the rising prevalence of psoriasis, advancements in therapeutic options, and ongoing research and development efforts. One of the primary growth drivers is the increasing awareness and diagnosis of psoriasis among healthcare professionals and patients. Improved understanding of the condition and its implications has led to more individuals seeking treatment, creating a larger patient base that requires effective therapeutic solutions.

The advancement of innovative therapies, particularly biologics and targeted treatments, is another key factor contributing to market growth. Biologics have transformed the treatment landscape for moderate to severe psoriasis, offering more effective and personalized solutions. The emergence of oral biologics and biosimilars is expected to further increase access to treatment and reduce costs, promoting the adoption of these therapies. The continuous development of new and improved treatment options is expected to fuel market growth as more effective therapies become available.

Ongoing research and development efforts in the field of dermatology are also supporting the growth of the psoriasis treatment market. Researchers are exploring new compounds and treatment modalities that target specific pathways involved in the pathogenesis of psoriasis. This focus on innovation is paving the way for the development of targeted therapies that can provide better outcomes for patients. The investment in R&D by biopharmaceutical companies is expected to lead to the introduction of novel treatment options, driving market expansion.

Moreover, the increasing focus on patient-centered care and holistic approaches to psoriasis management is creating new opportunities for the market. Healthcare providers are recognizing the importance of addressing the psychological and emotional impact of psoriasis, leading to integrated treatment approaches that include mental health support and lifestyle modifications. This trend towards comprehensive care is driving demand for multifaceted treatment solutions that can effectively address the complexities of psoriasis.

Additionally, the impact of the COVID-19 pandemic has heightened awareness of chronic health conditions, including psoriasis. As healthcare systems adapt to new challenges, there is a renewed focus on ensuring that patients receive the necessary care and support for their conditions. This emphasis on continuity of care is expected to drive the demand for psoriasis treatments, reinforcing the market`s growth trajectory.

As these factors converge, the global psoriasis treatment market is poised for robust growth, driven by advancements in therapeutic options, expanding patient awareness, and the increasing emphasis on improving health outcomes across various healthcare sectors.

Report Scope

The report analyzes the Psoriasis Treatment market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Drug Class (TNF Inhibitors Drug Class, Interleukins Inhibitors Drug Class, Other Drug Classs); Type (Plaque Psoriasis Type, Psoriatic Arthritis Type, Other Types); Product Type (Biologics Product Type, Non-Biologics Product Type); Administration Route (Oral Administration Route, Parenteral / Systemic Administration Route, Topical Administration Route); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Distribution Channel)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the TNF Inhibitors Drug Class segment, which is expected to reach US$25.6 Billion by 2032 with a CAGR of a 12.0%. The Interleukins Inhibitors Drug Class segment is also set to grow at 7.9% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $8.4 Billion in 2025, and China, forecasted to grow at an impressive 14.6% CAGR to reach $14.1 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Psoriasis Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Psoriasis Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Psoriasis Treatment Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AbbVie, Inc., Amgen, Inc., Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Psoriasis Treatment market report include:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 5,795 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind
  • Psoriasis Treatment - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Psoriasis and Psoriatic Arthritis Propels Growth in Psoriasis Treatment Market
  • Increasing Adoption of Biologic Therapies in Moderate to Severe Psoriasis Expands Addressable Market
  • Innovations in Topical Therapies Strengthen Business Case for Market Growth
  • Increasing Use of Psoriasis Treatment in Dermatology and Specialty Clinics Expands Market Scope
  • Technological Advancements in Oral and Injectable Biologics Propel Market Growth
  • Case Overview: Growth in Adoption of Psoriasis Treatments in At-Home and Over-The-Counter Products Expands Market Reach
  • Case Overview: Growth in Use of Psoriasis Treatment in Scalp and Nail Psoriasis Expands Market Reach
  • Technological Advancements in Light and Laser-Based Psoriasis Therapies Propel Market Growth
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Psoriasis Treatment Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Psoriasis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for TNF Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for TNF Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for TNF Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Interleukins Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Interleukins Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Interleukins Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Other Drug Classs by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Other Drug Classs by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Other Drug Classs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Plaque Psoriasis Type by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Plaque Psoriasis Type by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Plaque Psoriasis Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Psoriatic Arthritis Type by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Psoriatic Arthritis Type by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Psoriatic Arthritis Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 23: World Recent Past, Current & Future Analysis for Biologics Product Type by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 24: World Historic Review for Biologics Product Type by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 25: World 13-Year Perspective for Biologics Product Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 26: World Recent Past, Current & Future Analysis for Non-Biologics Product Type by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 27: World Historic Review for Non-Biologics Product Type by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 28: World 13-Year Perspective for Non-Biologics Product Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 29: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 30: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 31: World 13-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 32: World Recent Past, Current & Future Analysis for Parenteral / Systemic Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 33: World Historic Review for Parenteral / Systemic Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 34: World 13-Year Perspective for Parenteral / Systemic Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 35: World Recent Past, Current & Future Analysis for Topical Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 36: World Historic Review for Topical Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 37: World 13-Year Perspective for Topical Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 38: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 39: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 40: World 13-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 41: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 42: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 43: World 13-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 44: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 45: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 46: World 13-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
CANADA
JAPAN
  • Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
CHINA
  • Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
EUROPE
  • Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
FRANCE
  • Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
GERMANY
  • Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
ITALY
UNITED KINGDOM
  • Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
SPAIN
RUSSIA
REST OF EUROPE
AUSTRALIA
  • Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
  • Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
  • Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
  • Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.

Table Information